Han-Ni Hsieh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Han-Ni Hsieh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Ching Shen
Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
3 shared publications - Ching-Yeh Lin
Division of Hematology and Oncology, Changhua Christian Hospital, Changhua County, Taiwan
2 shared publications - Gwo-Chin Ma
Department of Genomic Medicine, Changhua Christian Hospital, Changhua 500, Taiwan
2 shared publications - Ming Chen
Department of Genomic Medicine and Center for Medical Genetics Changhua Christian Hospital Changhua Taiwan
2 shared publications - Shun-Ping Chang
Department of Genomic Medicine, Changhua Christian Hospital, Changhua 500, Taiwan
2 shared publications - Adeline Yan
Department of Genomic Medicine, Changhua Christian Hospital, Changhua 500, Taiwan
1 shared publication
Latest Publications
- Open Access
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3831
Non-Inversion Variants in Sporadic Hemophilia A Rarely Recur
Hemophilia A (HA), an X-linked bleeding disorder caused by Factor VIII (F8) gene mutations, persists in the population due to sporadic cases arising from de novo mutations. This study analyzed 24 pedigrees from hemophilia registries of multiple medical centers in Taiwan to assess whether sporadic non-inversion variants (NIVs) recur in the same generation within families. Linkage analysis using intragenic and extragenic markers combined with amplification refractory mutation system-quantitative polymerase chain reaction (ARMS-qPCR) revealed that among 16 individuals inheriting the same X chromosome as the one bearing the sporadic HA-causing mutation, none carried the F8 variant. These findings strongly suggest that sporadic NIVs exhibit very low risk of recurrence. Our results provide critical information for recurrence risk assessment and counseling strategies for HA sporadic NIVs.
- 25 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3831
Open AccessNon-Inversion Variants in Sporadic Hemophilia A Rarely Recur
Hemophilia A (HA), an X-linked bleeding disorder caused by Factor VIII (F8) gene mutations, persists in the population due to sporadic cases arising from de novo mutations. This study analyzed 24 pedigrees from hemophilia registries of multiple medical centers in Taiwan to assess whether sporadic non-inversion variants (NIVs) recur in the same generation within families. Linkage analysis using intragenic and extragenic markers combined with amplification refractory mutation system-quantitative polymerase chain reaction (ARMS-qPCR) revealed that among 16 individuals inheriting the same X chromosome as the one bearing the sporadic HA-causing mutation, none carried the F8 variant. These findings strongly suggest that sporadic NIVs exhibit very low risk of recurrence. Our results provide critical information for recurrence risk assessment and counseling strategies for HA sporadic NIVs.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (1) , 411-414
Acquired FXIII inhibitor: Patient characteristics and treatment outcome, a case series in Taiwan
- 1 January 2021
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 120 (1) , 411-414
Open AccessAcquired FXIII inhibitor: Patient characteristics and treatment outcome, a case series in Taiwan
- Open Access
- 4 October 2016
- Published by Springer Nature in Thrombosis Journal
- Vol. 14 (S1) , 3-8
De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD
Von Willebrand disease (VWD) is not uncommon in Taiwan. In type 2 or type 3 VWD hemorrhagic symptoms are severer and laboratory data relatively more distinctive. De novo mutation and somatic mosaicism of type 2 VWD gene were rarely reported. Therefore clinical, laboratory and genetic studies of only type 2A, 2B and 2M VWD will be presented and issues of de novo mutation and somatic mosaicism will be explored. Fifty-four patients belonging to 23 unrelated families from all around the country in whom type 2 VWD exclusive of type 2N has been diagnosed not only by clinical and routine laboratory studies but also by genetic confirmation during 1990–2015 were investigated. A novel technique named amplification refractory mutation system-quantitative polymerase chain reaction (ARMS-qPCR) was used to confirm the presence of somatic mosaicism. Informed consent was obtained for study. De novo mutation was identified in 4 families among 15 families (26.7 %) in whom family members including parents were available for examination. All their parents were free from bleeding symptoms and had no similar mutation as their respective affected daughter. An interesting example of somatic mosaicism of VWF gene mutation was found in a large family with type 2A VWD. The father carrying a mutated VWF gene, p.Arg1597Trp, transmitted this mutation to his 3 daughters, 1 son, 3 granddaughters and 2 grandsons. However, the father had normal laboratory findings and experienced no abnormal bleeding, while his offspring who inherited the mutation showed abnormal laboratory findings compatible with type 2A VWD and had history of abnormal bleedings. ARMS-qPCR revealed that the father had only 25.5 % mutant in his blood cells and 31.1 % mutant in his oral mucosal cells, while all his offspring had about 49 % mutant in their blood cells. De novo mutation of type 2 VWD gene was identified in 4 out of 15 families (26.7 %) examined. Since only one child was affected in each family, germline mosaicism was not likely. A somatic mosaicism of type 2A VWD gene was documented in a big family by a newly in-house developed technique ARMS-qPCR.
- 4 October 2016
- Published by Springer Nature in Thrombosis Journal
- Vol. 14 (S1) , 3-8
Open AccessDe novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD
Von Willebrand disease (VWD) is not uncommon in Taiwan. In type 2 or type 3 VWD hemorrhagic symptoms are severer and laboratory data relatively more distinctive. De novo mutation and somatic mosaicism of type 2 VWD gene were rarely reported. Therefore clinical, laboratory and genetic studies of only type 2A, 2B and 2M VWD will be presented and issues of de novo mutation and somatic mosaicism will be explored. Fifty-four patients belonging to 23 unrelated families from all around the country in whom type 2 VWD exclusive of type 2N has been diagnosed not only by clinical and routine laboratory studies but also by genetic confirmation during 1990–2015 were investigated. A novel technique named amplification refractory mutation system-quantitative polymerase chain reaction (ARMS-qPCR) was used to confirm the presence of somatic mosaicism. Informed consent was obtained for study. De novo mutation was identified in 4 families among 15 families (26.7 %) in whom family members including parents were available for examination. All their parents were free from bleeding symptoms and had no similar mutation as their respective affected daughter. An interesting example of somatic mosaicism of VWF gene mutation was found in a large family with type 2A VWD. The father carrying a mutated VWF gene, p.Arg1597Trp, transmitted this mutation to his 3 daughters, 1 son, 3 granddaughters and 2 grandsons. However, the father had normal laboratory findings and experienced no abnormal bleeding, while his offspring who inherited the mutation showed abnormal laboratory findings compatible with type 2A VWD and had history of abnormal bleedings. ARMS-qPCR revealed that the father had only 25.5 % mutant in his blood cells and 31.1 % mutant in his oral mucosal cells, while all his offspring had about 49 % mutant in their blood cells. De novo mutation of type 2 VWD gene was identified in 4 out of 15 families (26.7 %) examined. Since only one child was affected in each family, germline mosaicism was not likely. A somatic mosaicism of type 2A VWD gene was documented in a big family by a newly in-house developed technique ARMS-qPCR.